| Balance Sheets | 2026-06-30 | 2026-03-31 | 2025-12-31 | |
|---|---|---|---|---|
| Cash and cash equivalents | 223,143 | 238,902 | 96,358 | |
| Short-term investments | 11,043 | 12,100 | 11,078 | |
| Other receivables | 678 | 653 | 431 | |
| Prepaid expenses and other current assets | 1,597 | 1,707 | 901 | |
| Total current assets | 236,461 | 253,362 | 108,768 | |
| Other non-current assets | 759 | 789 | 492 | |
| Property and equipment, net | 4,785 | 2,745 | 2,339 | |
| Deferred offering costs | 0 | 0 | 2,715 | |
| Right-of-use asset | 1,428 | 1,490 | 1,552 | |
| Total assets | 243,433 | 258,386 | 115,866 | |
| Accounts payable | 4,155 | 3,514 | 2,696 | |
| Payroll-related accruals | 1,723 | 882 | 2,182 | |
| Other current liabilities | 3,559 | 2,271 | 3,706 | |
| Lease liability, current | - | - | 0 | |
| Redeemable convertible preferred stock tranche liability | - | - | 0 | |
| Total current liabilities | 9,437 | 6,667 | 8,584 | |
| Lease liability, non-current | 1,632 | 1,607 | 1,582 | |
| Total liabilities | 11,069 | 8,274 | 10,166 | |
| Redeemable convertible preferred stock, .00001 par value 0 shares authorized, issued, and outstanding as of june 30, 2026 116,618,581 shares authorized, 20,341,968 shares issued and outstanding as of december 31, 2025 (aggregate liquidation preference of 0 and 200,878,062 as of june 30, 2026 and december 31, 2025, respectively) | 0 | 0 | 204,537 | |
| Preferred stock, .00001 par value 200,000,000 shares authorized, 0 shares issued and outstanding as of june 30, 2026 0 shares authorized, issued, and outstanding as of december 31, 2025 | 0 | 0 | - | |
| Common stock, .00001 par value 1,000,000,000 shares authorized, 33,446,315 shares issued and outstanding as of june30, 2026 154,383,336 shares authorized 2,203,620 shares issued and outstanding as of december31, 2025 | 0 | 0 | 0 | |
| Common stock additional paid-in capital | 370,776 | 368,660 | 5,893 | |
| Accumulated deficit | -138,412 | -118,548 | -104,730 | |
| Total stockholders' equity (deficit) | 232,364 | 250,112 | -98,837 | |
| Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) | 243,433 | 258,386 | 115,866 | |
SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma, Inc. (SGP)